Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | EED | O75530 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11968406 | 0.89 | PTPN11 (0.40) | PTPN11L3MBTL1PRMT5WDR77EED | |
| SCHEMBL1516665 | 0.87 | TSHR (0.44) | PTPN11L3MBTL1PRMT5WDR77EED | |
| SCHEMBL11968501 | 0.85 | PTPN11 (0.39) | PTPN11L3MBTL1PRMT5WDR77EED | |
| SCHEMBL11968522 | 0.84 | PTPN11 (0.38) | PTPN11L3MBTL1PRMT5WDR77EED | |
| SCHEMBL11968527 | 0.84 | PTPN11 (0.37) | PTPN11L3MBTL1EEDBRD4POLB | |
| SCHEMBL11968507 | 0.83 | PTPN11 (0.38) | PTPN11L3MBTL1EEDBRD4HTR6 | |
| SCHEMBL11968458 | 0.82 | PTPN11 (0.44) | PTPN11L3MBTL1EEDBRD4GSK3A | |
| SCHEMBL11968473 | 0.81 | PTPN11 (0.37) | PTPN11L3MBTL1EEDBRD4GSK3A | |
| SCHEMBL11968500 | 0.81 | PTPN11 (0.37) | PTPN11L3MBTL1EEDBRD4 | |
| SCHEMBL31436019 | 0.81 | PTPN11 (0.46) | PTPN11L3MBTL1EEDBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242280-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242280-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-7906648-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906648-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-2264033-A1 | 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS | SGX Pharmaceuticals, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090306056-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306056-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| US-7601839-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS INC. (US) | 2009-10-13 | — | — | US | disclosed |
| WO-2008124849-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-7361763-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361763-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361764-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361764-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| WO-2007106236-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306056-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K19 | PTPN11 582/4885L3MBTL1 3181/4885PRMT5 745/4885 |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K19 | PTPN11 582/4885L3MBTL1 3181/4885PRMT5 745/4885 |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | MAP3K20, MAP4K2, MAP3K6 | PTPN11 697/4885L3MBTL1 2893/4885PRMT5 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.